Skip to main content

REVIEW article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1523743
This article is part of the Research Topic Recent Advances in Radiation Oncology for the Management of Thoracic Malignancies View all articles

Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review

Provisionally accepted
Lei Liu Lei Liu Yilong Mao Yilong Mao Leilei Guo Leilei Guo Chencong Li Chencong Li Yiqian Wang Yiqian Wang *
  • First Affiliated Hospital, Dalian Medical University, Dalian, China

The final, formatted version of the article will be published soon.

    Non-small cell lung cancer (NSCLC) is still the disease with the highest incidence rate among malignant tumors, in which NSCLC under N2 stage has obvious survival differences among different patients due to its high heterogeneity. For NSCLC under this stage, the current treatment options are: preoperative neoadjuvant therapy, surgical treatment, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy (PORT), Postoperative adjuvant targeted therapy and postoperative adjuvant immunotherapy. Whether postoperative adjuvant radiotherapy is routinely administered to patients with pN2 remains controversial in clinical application. Meanwhile, the booming development of adjuvant targeted therapy and adjuvant immunotherapy also provides newer therapeutic options for the prognosis of postoperative pN2 stage NSCLC, and some new markers will guide the adaptive application of immune drugs in the future. This article analyzes the current stage of therapeutic advances in operable stage N2 non-small cell lung cancer, and discusses in detail in this article the therapeutic controversy of postoperative adjuvant radiotherapy in pN2 stage non-small cell lung cancer, so as to explore a more reasonable treatment mode for future patients with stage N2 non-small cell lung cancer.

    Keywords: Non-small cell lung cancer, N2, Postoperative radiotherapy, postoperative immunotherapy, postoperative targeted therapy

    Received: 06 Nov 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Liu, Mao, Guo, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yiqian Wang, First Affiliated Hospital, Dalian Medical University, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.